N-(tert-butyl)-2-(5-iodo-4-methyl-2,6-dioxo-3-pentyl-2,3-dihydropyrimidin-1(6H)-yl)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-(tert-butyl)-2-(5-iodo-4-methyl-2,6-dioxo-3-pentyl-2,3-dihydropyrimidin-1(6H)-yl)acetamide
• 英文别名: N-tert-butyl-2-(5-iodo-4-methyl-2,6-dioxo-3-pentylpyrimidin-1-yl)acetamide
• 化学式: C₁₆H₂₆IN₃O₃
• 分子量: 435.305
• InChiKey: DQKWVTPUMXRCPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  69.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(tert-butyl)-2-(5-iodo-4-methyl-2,6-dioxo-3-pentyl-2,3-dihydropyrimidin-1(6H)-yl)acetamide 、 环丙基硼酸 在 potassium phosphate 、 palladium diacetate 、 三环己基膦 作用下， 以 水 、 甲苯 为溶剂， 反应 12.0h， 以65%的产率得到N-(tert-butyl)-2-(5-cyclopropyl-4-methyl-2,6-dioxo-3-pentyl-2,3-dihydropyrimidin-1(6H)-yl)acetamide
  参考文献：
  名称：

  Development of Quinazoline/Pyrimidine-2,4(1H,3H)-diones as Agonists of Cannabinoid Receptor Type 2

  摘要：

  Starting from a prototypical structure 1, we describe our efforts to design and obtain novel quinazoline/ pyrimidine-2,4(1H,3H)-diones with high CB2 agonist potency and selectivity as well as improved physicochemical characteristics, mainly hydrophilicity. The most potent and selective CB2 agonists, 8 and 36, in this series were also endowed with lower logP values than that of GW842166X and lead compound 1. These derivatives appear to be promising lead compounds for the development of future CB2 agonists.

  DOI：

  10.1021/acsmedchemlett.7b00007
• 作为产物：
  描述：

  6-甲基尿嘧啶 在 四丁基溴化铵 、 乙酸酐 、 sodium hydride 、 potassium carbonate 、 溶剂黄146 作用下， 以 乙二醇二甲醚 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 4.5h， 生成 N-(tert-butyl)-2-(5-iodo-4-methyl-2,6-dioxo-3-pentyl-2,3-dihydropyrimidin-1(6H)-yl)acetamide
  参考文献：
  名称：

  Development of Quinazoline/Pyrimidine-2,4(1H,3H)-diones as Agonists of Cannabinoid Receptor Type 2

  摘要：

  Starting from a prototypical structure 1, we describe our efforts to design and obtain novel quinazoline/ pyrimidine-2,4(1H,3H)-diones with high CB2 agonist potency and selectivity as well as improved physicochemical characteristics, mainly hydrophilicity. The most potent and selective CB2 agonists, 8 and 36, in this series were also endowed with lower logP values than that of GW842166X and lead compound 1. These derivatives appear to be promising lead compounds for the development of future CB2 agonists.

  DOI：

  10.1021/acsmedchemlett.7b00007